Stifel maintains Hold on Globus Medical, cuts target to $80
Stifel analyst Tom Stephan maintains a Hold rating on Globus Medical and lowers the price target to $80 from $95, reflecting a revised valuation outlook.
*this image is generated using AI for illustrative purposes only.
Stifel analyst Tom Stephan has maintained a Hold rating on Globus Medical and lowered the price target to $80 from $95. The revised target suggests a more conservative outlook for the company's stock performance.
The decision to reduce the price target comes as the firm reassesses the valuation of the medical device company. Despite the lower target, the Hold rating indicates that Stifel does not see a compelling reason to buy or sell the stock at current levels.
| Metric | Previous | Revised |
|---|---|---|
| Rating | Hold | Hold |
| Price Target | $95 | $80 |
Globus Medical, listed on the NYSE under the ticker GMED, continues to be monitored by analysts for its operational performance and market position. The new price target of $80 serves as a reference point for investors evaluating the stock's potential upside.
What specific factors led Stifel to reassess Globus Medical's valuation?
How might this price target reduction influence other analysts' ratings on GMED?
What upcoming operational milestones could shift Stifel's Hold rating?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
